Sudden Vision Loss With Jaw Claudication
A 76-year-old woman presents with sudden, painless loss of vision in the right eye that began 2 days ago. She describes a “curtain” over the eye and now can only count fingers at 2 feet. She reports several weeks of fatigue, scalp tenderness while combing her hair, and jaw pain when chewing. Her medications include amlodipine and atorvastatin. Visual acuity is counting fingers OD and 20/30 OS. There is a right relative afferent pupillary defect. Funduscopy shows a chalky-white, swollen optic disc with splinter hemorrhages at the margin; the left disc is normal. ESR is 92 mm/h and CRP is elevated. She asks whether she can start prednisone pills and see a rheumatologist next week.
1. What is your diagnosis, and why is immediate high-dose corticosteroid therapy indicated? Include the route, dose, and rationale in your answer.
Read the worked answer
Diagnosis: arteritic anterior ischemic optic neuropathy due to giant cell arteritis. The presentation-sudden painless vision loss, a relative afferent pupillary defect, a chalky-white swollen disc, elevated ESR and CRP, scalp tenderness, jaw claudication, and fatigue-is highly suggestive. The fellow eye is at high risk.
Why immediate steroids: giant cell arteritis is a medical emergency because involvement of the second eye can occur within days to weeks. Starting treatment before confirmation is standard; do not wait for a biopsy. High-dose corticosteroids reduce inflammation in the arterial wall and lower the risk of contralateral visual loss.
Regimen: methylprednisolone 1 g intravenously daily for 3 days, followed by oral prednisone 1 mg/kg/day (usually 60–80 mg/day). If intravenous therapy is not feasible, start oral prednisone 1 mg/kg/day immediately and arrange urgent admission or infusion. Do not use low-dose steroids. Provide gastric protection and monitor glucose, blood pressure, and electrolytes.
Counseling: explain that vision in the affected eye may not recover, but the primary goal is to protect the fellow eye. She should not wait until next week; she needs same-day treatment and urgent rheumatology or internal medicine involvement. Arrange admission or close observation depending on her stability.
2. When should the temporal artery biopsy be performed, and how do you interpret a negative biopsy in a patient with this presentation?
Read the worked answer
Timing: perform the temporal artery biopsy promptly, ideally within 1–2 weeks of starting corticosteroids. Do not delay steroids to obtain the biopsy. The histologic changes of giant cell arteritis can persist for up to 2 weeks after steroids are started, so a biopsy in that window remains useful. Obtain a segment at least 1–2 cm long and consider bilateral biopsy if the first is negative and clinical suspicion remains high, because the disease can be segmental.
Interpretation: a positive biopsy showing granulomatous inflammation, giant cells, or fragmentation of the internal elastic lamina confirms the diagnosis. A negative biopsy does not exclude giant cell arteritis, especially if the specimen is small, if the patient has already received prolonged steroids, or if the clinical picture is strong. In a patient with classic symptoms, elevated inflammatory markers, and arteritic anterior ischemic optic neuropathy, treat empirically and do not stop steroids solely because the biopsy is negative.
Additional evaluation: obtain CBC, comprehensive metabolic panel, and inflammatory markers; consider magnetic resonance angiography or temporal artery ultrasound if available, but these are adjuncts, not replacements for biopsy. Rheumatology should co-manage. The key judgment is that clinical diagnosis drives treatment, and biopsy is confirmatory.
3. Outline the long-term corticosteroid plan and monitoring, and explain how you would counsel the patient about prognosis and prevention of fellow-eye involvement.
Read the worked answer
Long-term plan: after high-dose therapy, continue oral prednisone at about 1 mg/kg/day and taper slowly over months, guided by symptoms and inflammatory markers. Tapering too quickly risks relapse and fellow-eye involvement. Rheumatology typically manages the taper and may add a steroid-sparing agent such as tocilizumab or methotrexate if relapses occur or steroids cannot be reduced. Low-dose aspirin is often recommended unless contraindicated.
Monitoring: check blood pressure, blood glucose or HbA1c, electrolytes, and renal function regularly. Obtain baseline bone density and recommend calcium and vitamin D; consider a bisphosphonate for osteoporosis prevention. Monitor for cataract, glaucoma, and infection. Watch for adrenal insufficiency during taper. Repeat inflammatory markers to guide therapy, but treat the clinical picture rather than markers alone.
Counseling: explain that vision in the right eye may remain poor, but the main goal is to prevent the same process in the left eye. Emphasize that steroids must not be stopped abruptly and that any new visual symptoms, jaw pain, headache, or scalp tenderness require immediate contact. She should carry medical alert information. The overall judgment is to treat aggressively at the first sign of arteritic disease and to maintain a slow, monitored taper with rheumatology involvement.